For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Immune Modulator

Thymogen

Also known as: Thymagen

Thymogen (also marketed as Thymagen) is a synthetic dipeptide, L-Glu-L-Trp (Glu-Trp), originally isolated by the Khavinson group from the calf-thymus polypeptide complex Thymalin and then synthesized. It is registered as a pharmaceutical in Russia for immunocorrection (nasal drops / IM injection). Not FDA-approved in the US; research-use only.

Where to buy · live market data

Who's worth your money for Thymogen

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (96) of 1 scored sellers

$4.00/mg

$79.97 · 20mg · 99.7% purity

2 COAs
Buy code MERIT · 15% off

Average price

$3.92/mg

Sellers

15

45-day trend

-30.6%

12 of 15 sellers have a current price· 9 stale hidden· 2 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Thymogen

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Thymogen

CAS

38101-59-6

Molecular formula

C16H19N3O5

Sequence

EW

Typical dose range

100 mcg/day intramuscular (approved Russian protocol, 3–10 day course; 300–1000 mcg total per course); nasal spray 25 mcg/nostril twice daily x 10 days

Half-life

~20–30 minutes (vendor-cited estimate; no formal Western-standard PK study available)

Research depth

12 citations indexed for Thymogen

All research on Thymogen →

review · 2026

Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia

Leukopenia remains a major clinical challenge associated with infectious diseases, oncological therapies, autoimmune disorders, and metabolic and iatrogenic conditions.

animal · 2025

Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats

We studied the reparative and antioxidant effects of thymogen (10 and 100 μg/kg) and its modifications in equimolar doses (12 and 120 μg/kg) obtained by attaching the amino acid D-alanine (D-Ala) to the N- or C-terminus of the peptide molecule.

review · 2024

The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples

Peptides show high promise in the targeting and intracellular delivery of next-generation biotherapeutics. The main limitation is peptides' susceptibility to proteolysis in biological systems. Numerous strategies have been developed to overcome this challenge by chemically enhancing the resistance to proteolysis.

Study · 2023

Reparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage

We studied the reparative and antioxidant effects of Thymogen and its new structural analogues obtained by binding amino acid D-Ala to the N- or C-end of the peptide molecule in acute toxic hepatopathy.

review · 2023

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

The oral delivery of peptide pharmaceuticals has long been a fundamental challenge in drug development. A new chemical platform was designed based on branched piperazine-2,5-diones for creating orally available biologically active peptidomimetics.

Study · 2022

Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line

This study evaluates the effects of five different peptides, the Epitalon ® tetrapeptide, the Vilon ® dipeptide, the Thymogen ® dipeptide, the Thymalin ® peptide complex, and the Chonluten ® tripeptide, as regulators of inflammatory and proliferative processes in the human monocytic THP-1, which is a human leukemia mon…